A Phase 2 Study of Zanubrutinib in Previously Treated B-Cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib: Preliminary Results for Patients With CLL/SLL

Video

Key opinion leader Mazyar Shadman, MD, MPH, reviews data from a clinical trial studying zanubrutinib in the context of ibrutinib- and/or acalabrutinib-intolerant CLL/SLL.

Related Videos
Alexey Danilov, MD, PhD, an expert on mantle cell lymphoma
John N. Allan, MD
Nicole Lamanna, MD
Mark A. Socinski, MD, an expert on lung cancer, presenting slides
Hope Rugo, MD, an expert on breast cancer, presenting slides
Expert on NSCLC
Brian Slomovitz, MD, an expert on cervical cancer, presenting data
Related Content
FDA Approves Pirtobrutinib for Previously Treated CLL/SLL

FDA Approves Pirtobrutinib for Previously Treated CLL/SLL

December 1st 2023
Article
Talal Hilal, MD, MB, BCh

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023
Podcast
Nicole Lamanna, MD

Overcoming Resistance Mutations Is a Focus for Novel Therapies in R/R CLL

November 21st 2023
Article
Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022
Podcast
The FDA has granted priority review to the supplemental biologics license application seeking approval to expand the indication of lisocabtagene maraleucel to include patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a BTK inhibitor and a BCL-2 inhibitor.

FDA Grants Priority Review to Liso-Cel for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

November 9th 2023
Article
Nicole Lamanna, MD

Lamanna Details Evolution of CLL Treatment Following Resistance

November 9th 2023
Article